

SAFETY AND EFFICACY OF SILDOSIN FOR THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA

Thesis

Submitted for partial fulfillment of
Master Degree in Urology
Faculty of Medicine – Cairo University

Presented By

Ahmed Mansour Abd El kader
M.B., B.Ch

Under the supervision of

Prof. Dr. Sherif Abd El-Rahman

Professor of Urology
Faculty of Medicine

Prof. Dr. Mostafa Abd El-Mohsen

Professor of Urology
Faculty of Medicine

Ass. Prof. Dr. Ashraf Emran

Assistant Professor of Urology
Faculty of Medicine

Faculty of Medicine
Cairo University
2016



بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ
قَالُوا سُبْحَانَكَ لَا عِلْمَ لَنَا إِلَّا مَا عَلَّمْتَنَا
إِنَّكَ أَنْتَ الْعَلِيمُ الْحَكِيمُ

صدق الله العظيم

سورة البقرة آية (32)

Acknowledgements

*First and foremost, I feel always indebted to Allah, the
Most Kind and Most Merciful*

*I would like to express my deep thanks to **Prof. Dr. Sherif Abd El-
Rahman** Professor of Urology, Faculty of Medicine, Cairo
University, I am deeply indebted to him for support, patience and
guidance which given me from his precious time.*

*I would like to express my sincere appreciation and deep
gratitude to **Prof. Dr. Mostafa Abd El-Mohsen**, Professor
of Urology Faculty of Medicine, Cairo University for his
great help, generous advice, sincere encouragement,
continuous support guided in my steps in this work and
unlimited assistance.*

*I would like to express my sincere appreciation and deep gratitude
to **Ass. Prof. Dr. Ashraf Emran** Assistant Professor of
Urology Faculty of Medicine, Cairo University for his great
help, patience and guidance.*

LIST OF CONTENTS

Introduction.....	1
Aim of Work.....	4
Anatomy of Prostate	5
Vascular Supply	10
Lymphatic drainage	12
Nerve Supply	13
Physiology and pathophysiology of LUT.....	15
Mechanisms of voiding.....	17
Pathophysiology of voiding.....	18
Pathophysiology of Bladder Outlet Obstruction (BOO).....	20
1- Stage of compensation	20
2- Stage of Decompensation	21
Bladder response to BOO	22
Benign prostatic hyperplasia	24
Alpha1-adrenergic receptor blockers	25
Historical background.....	27
The uroselectivity of silodosin	28
The pharmacokinetics of Silodosin	29
PATIENTS & METHODS	
Study design	31
Study population.....	31
Methodology Study	32
Clinical examination including.....	34
Statistical analysis	37
RESULTS	49
Efficacy Results	40
Quality of life related to urinary symptoms (IPSS-QoL)	46
The maximum flow rate (Qmax)	51
The post-void residual urine (PVR.....	57

Safety results.....	62
The supine diastolic blood pressure (D.BP)	67
Heart Rate (HR)	72
Treatment-emergent adverse events (TEAEs).....	77
Headache	79
Postural hypotension	80
DISCUSSION	92
SUMMARY	102
CONCLUSION	104
REFERENCES	105
ARABIC SUMMARY.....	

LIST OF TABLES

Table(1): Summary of studies for uroselectivity of $\alpha 1$ -adrenergic receptor antagonists	29
Table(2): Ranges of ages in the three groups	38
Table(3): Age distribution in the three groups	38
Table(4): Summary of the baseline characteristics of the total patients screened in the three study groups.....	39
Table(5): The overall four visits records of IPSS among patients in the three groups A, B and C.....	40
Table(6): Comparison of IPSS changes from baseline to endpoint of the study between the groups A and C (based on adjusted means).....	42
Table(7): Comparison of IPSS changes from baseline to endpoint of the study between the groups B and C (based on adjusted means).....	43
Table(8): Comparison of IPSS changes from baseline to endpoint of the study between the groups A and B (based on adjusted means).....	44
Table(9): Response rates according to total IPSS in the three study groups A, B and C.....	45
Table(10): The overall four visits records of IPSS-QoL among patients of the three V groups A, B and C.....	46
Table(11): Comparison of IPSS-QoL score changes from baseline to endpoint of the study between the two groups A and C (based on adjusted means).....	48
Table(12): Comparison of IPSS-QoL score changes from baseline to endpoint of the study between the two groups B and C (based on adjusted means).....	49
Table(13): Comparison of IPSS-QoL score changes from baseline to endpoint of the study between the two groups A and B (based on adjusted means).....	50
Table(14): The overall four visits measurements of Q _{max} among patients of the three groups of the study A, B and C.....	51
Table(15): Comparison of Q _{max} changes from baseline to endpoint of the study between the two groups A and C (based on adjusted means).....	53

Table(16): Comparison of Qmax changes from baseline to endpoint of the study between the two groups B and C (based on adjusted means)	54
Table(17): Comparison of Qmax changes from baseline to endpoint of the study between the two groups A and B (based on adjusted means)	55
Table(18): Response rates according to Qmax in the three study groups A, B and C	56
Table(19): Response rates according to Qmax in the three study groups A, B and C	57
Table(20): The overall four visits assessment of PVR among patients of the three groups of the study	59
Table(21): Comparison of PVR changes from baseline to endpoint of the study between the two groups A and C (based on adjusted means)	60
Table(22): Comparison of PVR changes from baseline to endpoint of the study between the two groups B and C (based on adjusted means)	61
Table(23): Comparison of PVR changes from baseline to endpoint of the study between the two groups A and B (based on adjusted means)	62
Table(24): The overall four visits measurements of Systolic blood pressure (S.BP) among patients of the three groups of the study	64
Table(25): Comparison of systolic blood pressure changes from baseline to endpoint of the study between the two groups A and C (based on adjusted means)	65
Table(26): Comparison of systolic blood pressure changes from baseline to endpoint of the study between the two groups B and C (based on adjusted means)	66
Table(27): Comparison of systolic blood pressure change from baseline to endpoint of the study between the two groups A and B (based on adjusted means)	67
Table(28): The overall four visits measurements of Diastolic blood pressure (D.BP) among patients of the three groups of the study	69

Table(29): Comparison of Diastolic blood pressure change from baseline to endpoint of the study between the two groups A and C (based on adjusted means)	70
Table(30): Comparison of Diastolic blood pressure change from baseline to endpoint of the study between the two groups B and C (based on adjusted means)	71
Table(31): Comparison of Diastolic blood pressure change from baseline to endpoint of the study between the two groups A and B (based on adjusted means)	72
Table(32): The overall four visits measurements of heart rate (HR) among patients of the three groups of the study	74
Table(33): Comparison of Heart rate change from baseline to endpoint of the study between the two groups A and C (based on adjusted means)	75
Table(34): Comparison of Heart rate change from baseline to endpoint of the study between the two groups B and C (based on adjusted means)	76

LIST OF FIGURES

Fig.(1):	Sagittal section through the prostatic and membranous urethra, demonstrating the midline relations of the pelvic structures.	5
Fig.(2):	Posterior wall of the male urethra.....	6
Fig.(3):	Retrograde urethrogram of the male urethra demonstrating urethral anatomy. 1, prostatic urethra; 2, verumontanum, into which enter the ejaculatory ducts; 3, membranous urethra, note physiologic narrowing of urethral luminal diameter due to external striated sphincter; 4, bulbar urethra; 5, pendulous urethra.....	7
Fig.(4):	Zonal anatomy of the prostate as described by J.E. McNeal (Normal histology of the prostate. Am J SurgPathol 1988;12:619–33). The transition zone surrounds the urethra proximal to the ejaculatory ducts. The central zone surrounds the ejaculatory ducts and projects under the bladder base. The peripheral zone constitutes the bulk of the apical, posterior, and lateral aspects of the prostate. The anterior fibromuscularstroma extends from the bladder neck to the striated urethral sphincter.....	8
Fig.(5):	Transrectal ultrasound of the prostate demonstrating the 1, peripheral zone and 2, transition zone.	9
Fig.(6):	Arterial supply of the prostate (Adapted from Flocks RH. The arterial distribution within the prostate gland: its role in transurethral prostatic resection.....	11

Fig.(7):	Pelvic venous plexus. A, Trifurcation of the dorsal vein of the penis, viewed from the retropubic space. The relationship of the venous branches to the puboprostatic ligaments is shown. B, Lateral view of the pelvic venous plexus after removal of the lateral pelvic fascia. Normally these structures are difficult to see because they are embedded in pelvic fascia	12
Fig.(8):	Lymphatic drainage of the male pelvis, perineum, and external genitalia.	13
Fig.(9):	Innervation to lower urinary tract, prostate, and external sphincter (efferent and afferent pathways). Stars mean possible lesions for lower urinary tract dysfunction.....	16
Fig.(10):	The balance between sympathetic and parasympathetic nerves and the post-synaptic receptors involved during voiding and urinary storage	16
Fig.(11):	The International Prostate Symptom Score (IPSS)	33

LIST OF CHARTS

Chart (1) IPSS improvement rate in the three groups.	41
Chart (2) IPSS-QoL improvement rate in the three groups.	47
Chart (3) Qmax improvement rate in the three groups	52
Chart (4) PVR improvement rate in the three groups.	58
Chart (5) S.BP decrease rate in the three groups.	63
Chart (6) D.BP decrease rate in the three groups.....	68
Chart (7) HR increase rate in the three groups	73.

LIST OF ABBREVIATIONS

ATP:	Adenosine triphosphate
BOO:	Bladder outlet obstruction
BPH:	Benign prostatic hyperplasia
BWT:	Bladder wall thickness
C/S:	Culture and sensitivity
CBC:	Complete blood count
CI:	Confidence interval
ED:	Erectile dysfunction
EjD:	Ejaculatory dysfunction
DRE:	Digital rectal examination
ECG:	Electrocardiogram
IBM:	International business machine
IPPS:	International Prostate Symptom Score
IPSS-QoL:	Quality of life related to urinary symptoms
LUTs:	Lower urinary tract symptoms
LUTs/BPH:	Lower urinary tract symptoms associated with benign prostatic hyperplasia
MSAM-7:	Multinational Survey of the Aging Male-7
NANC:	Non-adrenergic non-cholinergic
NO:	Nitric oxide
PSA:	Prostatic specific antigen
PVR:	Post void residue
Qmax:	Maximum urinary flow rate
QoL:	Quality of life
SMCs:	Smooth muscle cells
SPSS:	Statistical package for social science
St.D:	Standard deviation

TEAEs:	Treatment-emergent adverse events
TOWC:	Trial without catheter
TRUS:	Trans rectal ultra-sound
U/S:	Ultra-sound
UT:	Urinary tract

Abstract

Background: α_1 adrenergic receptor antagonists are commonly used as the first-line treatments for LUTS associated with BPH. Silodosin is a novel α_1 -adrenergic receptor antagonist whose affinity for the α_{1A} -adrenergic receptor is 162 times higher than that for the α_{1B} -adrenergic receptor, and 55 times higher than that for the α_{1D} -adrenergic receptor. Therefore, silodosin does not increase the incidence of blood pressure-related side effects, which are mainly result from the inhibition of the α_{1B} -adrenergic receptor.

Objective: To test the hypothesis that the efficacy of silodosin(in dose of 8 mg once daily) would not be inferior to tamsulosin (in dose of 0.4 mg once daily) in treating patients with LUTS associated with BPH, with lesser cardiovascular side effects (as judged by the minimal changes of blood pressure and heart rate after treatment).

Design, setting, and participants: A randomized, double-blind, placebo- and active-controlled, parallel-group study assessed men ≥ 50 yrs. of age with LUTS/BPH, International Prostate Symptom Score (IPSS) ≥ 13 , Post Voiding Residue(PVR) ≤ 150 ml and maximum urinary flow rate (Qmax) between 4 and 15 ml/s. Following screening, subjects completed a 24-wk silodosin 8 mg once daily, tamsulosin 0.4 mg once daily and placebo.

Measurements: Outcomes were assessed by change from baseline in IPSS, quality of life (QoL), Qmax, PVR, systolic blood pressure (S.BP), diastolic blood pressure (D.BP) and heart rate (HR) to endpoint of the study. Responders to the treatments on the basis of IPSS decrease of $\geq 25\%$ and Qmax increase of $\geq 30\%$ were calculated.

Results: Silodosin and tamsulosin significantly improved IPSS total score in comparison with placebo ($p=0.005$) and($p=0.007$), respectively. Silodosin and tamsulosin significantly improved QoL ($p<0.0001$) and ($p<0.0001$), respectively. Silodosin and tamsulosin significantly improved Qmax ($p<0.0001$) and ($p<0.0001$), respectively. Silodosin and tamsulosin significantly improved PVR ($p<0.0001$) and($p=0.022$), respectively, with highly statistically significant difference between both ($p<0.0001$). However, regarding systolic blood pressure, a minor but statistically significant change versus placebo was observed with tamsulosin ($p=0.026$) and for a lesser extent with silodosin but non-significant ($p = 0.177$). Similarly, diastolic blood pressure had hardly statistically significant change with tamsulosin ($p = 0.058$), while statistically non-significant change in diastolic blood pressure occurred with silodosin ($p=0.387$). While both silodosin and tamsulosin did not affect heart rate significantly ($p = 0.204$) and ($p = 0.515$), respectively, with statistically significant difference between both of them ($p = 0.025$). In silodosin group, a retrograde ejaculation was reported in 10 patients from 35 patients were sexually active (28.6%) and only one subject reported headache. While in tamsulosin group, a retrograde ejaculation was reported in 1 patients from 36 patients were sexually active (2.8%), three subjects reported headache and three reported postural hypotension.

Conclusions: Silodosin is not only comparable to tamsulosin in treatment of LUTS/BPH, but also superior numerically, with higher safety profile. However, retrograde ejaculation is considered troublesome for sexually active patients.

Keywords: Silodosin, tamsulosin, benign prostatic hyperplasia, Lower urinary tract symptoms, quality of life, α_1A adrenergic receptors.

INTRODUCTION

Benign Prostatic Hyperplasia (BPH) is a non-malignant enlargement of the prostate caused by cellular hyperplasia of both glandular and stromal elements (*Chapple, 1992*).

Benign prostatic hyperplasia (BPH) is a common progressive disease among men, with an incidence that is age-dependent. Histological BPH, which typically develop after the age of 40 years, ranges in prevalence from >50% at 60 years to as high as 90% by 85 years of age. BPH contribute to, but is not the single cause of, bothersome lower urinary tract symptoms (LUTS) that may affect quality of life. The prevalence of troublesome symptoms increases with age, with symptoms typically occurring in men aged ≥ 50 years. Approximately 50% of patients with histological BPH report moderate to severe LUTS, consisting of storage and voiding symptoms. Although bothersome LUTS may affect quality of life by altering normal daily activities and sleep patterns, mortality associated with BPH is rare. Although uncommon, serious complications of BPH may occur, including acute urinary retention, renal insufficiency, urinary tract infection, hematuria, bladder stone, and renal failure (*Yoshida et al., 2011*).

These complications may be triggered or worsened by inadequate management of BPH. The incidence of acute urinary retention in untreated patients ranges from 0.3% to 3.5% per year; the risk of developing other long-term complication is unclear (*O'Leary, 2003*).

The management of patients with BPH includes non-pharmacological, pharmacological, and surgical option, with the choice of therapy typically depending on the presence and severity of symptoms. Watchful waiting is the preferred management strategy for patients with